Table 1.
Clinical characteristics of patients with echinocandins-associated coagulation dysfunction events
| No. of coagulation dysfunction events in echinocandins (%) | No. of other AEs in echinocandins (%) | |
|---|---|---|
| Reports | 313 | 4395 |
| Gender | ||
| Male | 175 (55.91) | 2300 (52.33) |
| Female | 116 (37.06) | 1538 (34.99) |
| Unknown | 22 (7.03) | 557 (12.67) |
| Age | ||
| < 20 | 32 (10.22) | 442 (10.06) |
| ≥ 20 and < 40 | 32 (10.22) | 475 (10.81) |
| ≥ 40 and < 60 | 63 (20.13) | 939 (21.37) |
| ≥ 60 | 146 (46.65) | 1325 (30.15) |
| Reporter | ||
| Healthcare workers | 242 (77.32) | 3130 (71.22) |
| Non-health care workers | 64 (20.45) | 1154 (26.26) |
| Unknown | 7 (2.24) | 111 (2.53) |
| Year | ||
| 2021–2024 | 25 (7.99) | 597 (13.58) |
| 2016–2020 | 51 (16.29) | 1497 (34.06) |
| 2011–2015 | 89 (28.43) | 1359 (30.92) |
| 2004–2010 | 117 (37.38) | 941 (21.41) |
| Outcome | ||
| Death | 167 (53.35) | 1579 (35.93) |
| Life-threatening | 71 (22.68) | 365 (8.30) |
| Disability | 17 (5.43) | 51 (1.16) |
| Hospitalization | 101 (32.27) | 1128 (25.67) |
| Other serious | 190 (60.70) | 1848 (42.05) |
| Congenital Anomaly | 0 (0) | 3 (0.07) |
| Required intervention | 1 (0.32) | 12 (0.27) |
| Report countries (Top 3) | Japan 51 (16.29) | America 960 (21.84) |
| China 30 (9.58) | Japan 480 (10.92) | |
| America 15 (4.79) | France 277 (6.30) | |
| Indications (Top 3) | Prophylaxis 57 (18.21) | Fungal infection 596 (13.56) |
| Febrile neutropenia 49 (15.65) | Febrile neutropenia 329 (7.49) | |
| Fungal infection 39 (12.46) | Bronchopulmonary aspergillosis 293 (6.67) | |
| Onset time (Median [IQR] / d) | 3 (1–8) | - |